Skip to main content

Epilepsy Pharmacogenomics: delivering biomarkers for clinical use

Objective

The purpose of the project is to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs).
The need for improved treatments in epilepsy is undoubted. Epilepsy is affects 50,000,000 people of all ages worldwide. Epilepsy is serious, increasing morbidity across all aspects of life, including a high risk of premature mortality. Over 20 antiepileptic drugs (AEDs) are licenced for its treatment. Seizures can be effectively controlled by AEDs in ~70% of people. Control of seizures leads to risk reduction for most of consequences of epilepsy, improves quality of life, permits social re-integration and leads to direct economic benefits. However, in 30% of patients, currently-available AEDs do not control seizures – recurrent seizures threaten life and impair its quality in these patients, and account for much of the €15.5 billion annual cost of epilepsy in the EU alone; there is currently no way to predict which patients will not respond to any or all AEDs; even in the 70% who do respond, only 47% respond to the first AED – whilst the correct drug is being sought, risks from seizures continue – we need to be able to predict the right drug for an individual from the outset; unrelated to responder status, AEDs can cause serious ADRs – a biomarker exists for only one ADR; there is a clear need for novel means of discovery of new AEDs – existing AEDs are anti-seizure drugs, not disease-modifying drugs.
We will use genome-wide analyses, including next-generation sequencing, in large, well-phenotyped patient cohorts to identify genome-based biomarkers, to improve use of current AEDs and identify new therapy targets.
SMEs, which are central to this project, will be able to take the data forward for development of clinical tests; data will also be invaluable for industry seeking to develop new treatments.

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Coordinator

UCL Elizabeth Garrett Anderson Institute for Women’s Health
Address
Gower Street
WC1E 6BT London
United Kingdom

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Greta Borg-Carbott (Ms.)
EU contribution
€ 1 066 961

Participants (14)

UNIVERSITE LIBRE DE BRUXELLES
Belgium
EU contribution
€ 283 761
Address
Avenue Franklin Roosevelt 50
1050 Bruxelles

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Angélique Greindl (Ms.)
ISTITUTO GIANNINA GASLINI
Italy
EU contribution
€ 252 864
Address
Via Gerolamo Gaslini 5
16147 Genova

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
Maria Gabriella Marinari (Dr.)
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 411 802
Address
Geschwister-scholl-platz
72074 Tuebingen

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Holger Lerche (Prof.)
Stichting Epilepsie Instellingen Nederland
Netherlands
EU contribution
€ 89 498
Address
Achterweg 5
2103 SW Heemstede

See on map

Activity type
Research Organisations
Administrative Contact
Gerland De Vries
UNIVERSITATSKLINIKUM BONN
Germany
EU contribution
€ 169 542
Address
Venusberg-campus 1
53127 Bonn

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Beate Becker
ROYAL COLLEGE OF SURGEONS IN IRELAND
Ireland
EU contribution
€ 323 536
Address
St Stephen's Green 123
2 Dublin

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Barry Mcgowan (Mr.)
BELFAST HEALTH AND SOCIAL CARE TRUST
United Kingdom
EU contribution
€ 100 752
Address
Lisburn Road Belfast City Hospital A Floor
BT9 7AS Belfast

See on map

Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Administrative Contact
John Craig (Dr.)
ISLENSK ERFDAGREINING EHF
Iceland
EU contribution
€ 2 146 572
Address
Sturlugotu 8
101 Reykjavik

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bjorgvin Richardsson (Mr.)
UNIVERSITE DU LUXEMBOURG
Luxembourg
EU contribution
€ 298 752
Address
2 Avenue De L'universite
4365 Esch-sur-alzette

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Rudi Balling (Prof.)
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 100 425
Address
Heidelberglaan 100
3584 CX Utrecht

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
E.Th. (Erik) Van Den Broek (Mr.)
THE UNIVERSITY OF LIVERPOOL
United Kingdom
EU contribution
€ 212 901
Address
Brownlow Hill 765 Foundation Building
L69 7ZX Liverpool

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Jenny Lawson (Ms.)
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 101 304
Address
South Kensington Campus Exhibition Road
SW7 2AZ London

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tatjana Palalic (Ms.)
UNIVERSITY OF GLASGOW
United Kingdom
EU contribution
€ 106 444
Address
University Avenue
G12 8QQ Glasgow

See on map

Activity type
Higher or Secondary Education Establishments
Administrative Contact
Joe Galloway (Mr.)
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG
Germany
EU contribution
€ 332 882
Address
Oskar Von Miller Ring 29
80333 Muenchen

See on map

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Birgit Fuchs (Mrs.)